FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Eur J Pharm Biopharm / Sustained intra-articular release of celecoxib in an equine ...
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V2018; 128; 327-336; doi: 10.1016/j.ejpb.2018.05.001

Sustained intra-articular release of celecoxib in an equine repeated LPS synovitis model.

Abstract: Synovial inflammation is an important characteristic of arthritic disorders like osteoarthritis and rheumatoid arthritis. Orally administered non-steroidal anti-inflammatory drugs (NSAIDs) such as celecoxib are among the most widely prescribed drugs to manage these debilitating diseases. Intra-articular delivery in biodegradable in situ forming hydrogels overcomes adverse systemic effects and prolongs drug retention in the joint. In this study two formulations of celecoxib (40 mg/g and 120 mg/g) in a propyl-capped PCLA-PEG-PCLA triblock copolymer were sequentially evaluated in a multiple LPS challenge equine synovitis model. Intra-articular release and systemic exposure to celecoxib and local changes at joint level were evaluated longitudinally. A single intra-articular injection of the high dose (HCLB)-gel or low dose (LCLB)-gel showed a sustained and controlled intra-articular release in both inflamed and healthy joints together with very low systemic exposure. Synovitis and lameness were moderate respectively very mild in this model due to the low concentration LPS (0.25 ng/joint). Both celecoxib formulations had a mild, transient effect on inflammatory and structural synovial fluid biomarkers but these returned to baseline within one week of administration. The HCLB-gel showed a significant inhibition in peak white blood cell concentration at 8 h after LPS induction. Elevated levels of celecoxib were observed in the joint for up to 30 days but no overall anti-inflammatory effects could be observed, which was thought to be due to the moderate synovitis. As there were no long-term adverse effects, sustained intra-articular release of celecoxib from in situ forming hydrogels should be evaluated further for its effects on longer-term relief of inflammatory joint pain in humans and animals.
Copyright © 2018 Elsevier B.V. All rights reserved.
Get Full Text
Publication Date: 2018-05-03 PubMed ID: 29729412DOI: 10.1016/j.ejpb.2018.05.001Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research article presents a study on the sustained release of celecoxib, a non-steroidal anti-inflammatory drug (NSAID), specifically within the joint space using an in situ forming hydrogel, for treating synovial inflammation commonly found in arthritic disorders like osteoarthritis and rheumatoid arthritis.

Research Objectives and Methodology

The core aim of the researchers was to develop an effective treatment for joint inflammation by administering celecoxib directly into the joint. The researchers incorporated celecoxib into a propyl-capped PCLA-PEG-PCLA triblock copolymer hydrogel and injected it directly into the joint space.

  • The primary focus was to reduce undesirable systemic side effects associated with oral administration while maintaining effective concentrations of the drug in the joint space.
  • The researchers used an equine model with repeated lipopolysaccharide (LPS) induced synovitis to evaluate the effect of two different concentrations of celecoxib (40 mg/g and 120 mg/g).
  • The intra-articular release of the drug, systemic exposure to celecoxib and local changes at the joint level were measured over a period of time.

Research Findings

The findings from the study showed that a single injection of the high dose (HCLB)-gel or low dose (LCLB)-gel resulted in a regulated and sustained release of celecoxib within the joint, with minimal systemic exposure.

  • The induced synovitis and lameness in the model were moderate and very mild respectively due to the low LPS concentration used.
  • Both celecoxib formulations resulted in a mild, transient effect on the inflammatory and structural biomarkers in the synovial fluid, which returned to baseline within a week.
  • The higher concentration celecoxib formulation significantly inhibited the peak white blood cell concentration 8 hours after LPS induction, indicating a reduction in the inflammation response.
  • Elevated levels of the celecoxib drug were observed in the joint for up to 30 days, although no overall anti-inflammatory effects were observed, possibly due to the moderate synovitis induced in this model.

Implications and Conclusions

The researchers concluded that despite not observing an overall anti-inflammatory effect in the equine model, the sustained release of celecoxib from within the joint using in situ forming hydrogels could still have potential therapeutic benefits.

  • This method may have advantages in terms of reducing systemic side effects and prolonging drug retention in the joint, which could potentially provide longer-term relief from inflammatory joint pain in human and animal patients.
  • However, further evaluation and research are recommended before any conclusive benefits can be established.

Cite This Article

APA
Cokelaere SM, Plomp SGM, de Boef E, de Leeuw M, Bool S, van de Lest CHA, van Weeren PR, Korthagen NM. (2018). Sustained intra-articular release of celecoxib in an equine repeated LPS synovitis model. Eur J Pharm Biopharm, 128, 327-336. https://doi.org/10.1016/j.ejpb.2018.05.001

Publication

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
ISSN: 1873-3441
NlmUniqueID: 9109778
Country: Netherlands
Language: English
Volume: 128
Pages: 327-336
PII: S0939-6411(17)30988-8

Researcher Affiliations

Cokelaere, Stefan M
  • Dept. Equine Sciences, Faculty of Veterinary Medicine, Utrecht University, Yalelaan 112, 3584 CM Utrecht, The Netherlands. Electronic address: S.M.Cokelaere@uu.nl.
Plomp, Saskia G M
  • Dept. Equine Sciences, Faculty of Veterinary Medicine, Utrecht University, Yalelaan 112, 3584 CM Utrecht, The Netherlands; Department of Orthopaedics, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.
de Boef, Esther
  • InGell Labs BV, L.J. Zielstraweg 1, 9713 GX Groningen, The Netherlands.
de Leeuw, Mike
  • InGell Labs BV, L.J. Zielstraweg 1, 9713 GX Groningen, The Netherlands.
Bool, Sophie
  • Dept. Equine Sciences, Faculty of Veterinary Medicine, Utrecht University, Yalelaan 112, 3584 CM Utrecht, The Netherlands.
van de Lest, Chris H A
  • Dept. Equine Sciences, Faculty of Veterinary Medicine, Utrecht University, Yalelaan 112, 3584 CM Utrecht, The Netherlands; Department of Biochemistry and Cell Biology, Faculty of Veterinary Medicine, Utrecht University, Yalelaan 2, 3584 CM Utrecht, The Netherlands.
van Weeren, P René
  • Dept. Equine Sciences, Faculty of Veterinary Medicine, Utrecht University, Yalelaan 112, 3584 CM Utrecht, The Netherlands.
Korthagen, Nicoline M
  • Dept. Equine Sciences, Faculty of Veterinary Medicine, Utrecht University, Yalelaan 112, 3584 CM Utrecht, The Netherlands; Department of Orthopaedics, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.

MeSH Terms

  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / administration & dosage
  • Biomarkers / analysis
  • Celecoxib / administration & dosage
  • Delayed-Action Preparations / administration & dosage
  • Disease Models, Animal
  • Female
  • Horses
  • Humans
  • Hydrogels / administration & dosage
  • Injections, Intra-Articular
  • Lipopolysaccharides / immunology
  • Male
  • Polyesters
  • Polyethylene Glycols
  • Synovial Fluid / chemistry
  • Synovitis / drug therapy
  • Synovitis / immunology

Citations

This article has been cited 22 times.
  1. Kearney CM, Khatab S, van Buul GM, Plomp SGM, Korthagen NM, Labberté MC, Goodrich LR, Kisiday JD, Van Weeren PR, van Osch GJVM, Brama PAJ. Treatment Effects of Intra-Articular Allogenic Mesenchymal Stem Cell Secretome in an Equine Model of Joint Inflammation. Front Vet Sci 2022;9:907616.
    doi: 10.3389/fvets.2022.907616pubmed: 35812845google scholar: lookup
  2. Ma L, Zheng X, Lin R, Sun AR, Song J, Ye Z, Liang D, Zhang M, Tian J, Zhou X, Cui L, Liu Y, Liu Y. Knee Osteoarthritis Therapy: Recent Advances in Intra-Articular Drug Delivery Systems. Drug Des Devel Ther 2022;16:1311-1347.
    doi: 10.2147/DDDT.S357386pubmed: 35547865google scholar: lookup
  3. Gupta A, Lee J, Ghosh T, Nguyen VQ, Dey A, Yoon B, Um W, Park JH. Polymeric Hydrogels for Controlled Drug Delivery to Treat Arthritis. Pharmaceutics 2022 Feb 28;14(3).
    doi: 10.3390/pharmaceutics14030540pubmed: 35335915google scholar: lookup
  4. Jacobs CC, Schnabel LV, McIlwraith CW, Blikslager AT. Non-steroidal anti-inflammatory drugs in equine orthopaedics. Equine Vet J 2022 Jan 25;54(4):636-48.
    doi: 10.1111/evj.13561pubmed: 35076950google scholar: lookup
  5. Cokelaere SM, Groen WMGAC, Plomp SGM, de Grauw JC, van Midwoud PM, Weinans HH, van de Lest CHA, Tryfonidou MA, van Weeren PR, Korthagen NM. Sustained Intra-Articular Release and Biocompatibility of Tacrolimus (FK506) Loaded Monospheres Composed of [PDLA-PEG(1000)]-b-[PLLA] Multi-Block Copolymers in Healthy Horse Joints. Pharmaceutics 2021 Sep 10;13(9).
    doi: 10.3390/pharmaceutics13091438pubmed: 34575514google scholar: lookup
  6. Oliveira IM, Fernandes DC, Cengiz IF, Reis RL, Oliveira JM. Hydrogels in the treatment of rheumatoid arthritis: drug delivery systems and artificial matrices for dynamic in vitro models. J Mater Sci Mater Med 2021 Jun 22;32(7):74.
    doi: 10.1007/s10856-021-06547-1pubmed: 34156535google scholar: lookup
  7. Mazaleuskaya LL, Muzykantov VR, FitzGerald GA. Nanotherapeutic-directed approaches to analgesia. Trends Pharmacol Sci 2021 Jul;42(7):527-550.
    doi: 10.1016/j.tips.2021.03.007pubmed: 33883067google scholar: lookup
  8. Christmann U, Hancock CL, Poole CM, Emery AL, Poovey JR, Hagg C, Mattson EA, Scarborough JJ, Christopher JS, Dixon AT, Craney DJ, Wood PL. Dynamics of DHA and EPA supplementation: incorporation into equine plasma, synovial fluid, and surfactant glycerophosphocholines. Metabolomics 2021 Apr 17;17(5):41.
    doi: 10.1007/s11306-021-01792-5pubmed: 33866431google scholar: lookup
  9. DeJulius CR, Gulati S, Hasty KA, Crofford LJ, Duvall CL. Recent Advances in Clinical Translation of Intra-Articular Osteoarthritis Drug Delivery Systems. Adv Ther (Weinh) 2021 Jan;4(1).
    doi: 10.1002/adtp.202000088pubmed: 33709019google scholar: lookup
  10. Salgado C, Jordan O, Allémann E. Osteoarthritis In Vitro Models: Applications and Implications in Development of Intra-Articular Drug Delivery Systems. Pharmaceutics 2021 Jan 5;13(1).
    doi: 10.3390/pharmaceutics13010060pubmed: 33466397google scholar: lookup
  11. Chakrabarti S, Ai M, Henson FMD, Smith ESJ. Peripheral mechanisms of arthritic pain: A proposal to leverage large animals for in vitro studies. Neurobiol Pain 2020 Aug-Dec;8:100051.
    doi: 10.1016/j.ynpai.2020.100051pubmed: 32817908google scholar: lookup
  12. Sotelo EDP, Vendruscolo CP, Fülber J, Seidel SRT, Jaramillo FM, Agreste FR, Silva LCLCD, Baccarin RYA. Effects of Joint Lavage with Dimethylsulfoxide on LPS-Induced Synovitis in Horses-Clinical and Laboratorial Aspects. Vet Sci 2020 Apr 30;7(2).
    doi: 10.3390/vetsci7020057pubmed: 32365982google scholar: lookup
  13. Gibson C, de Ruijter-Villani M, Bauersachs S, Stout TAE. Asynchronous Embryo Transfer Followed by Comparative Transcriptomic Analysis of Conceptus Membranes and Endometrium Identifies Processes Important to the Establishment of Equine Pregnancy. Int J Mol Sci 2020 Apr 7;21(7).
    doi: 10.3390/ijms21072562pubmed: 32272720google scholar: lookup
  14. Ziadlou R, Barbero A, Stoddart MJ, Wirth M, Li Z, Martin I, Wang XL, Qin L, Alini M, Grad S. Regulation of Inflammatory Response in Human Osteoarthritic Chondrocytes by Novel Herbal Small Molecules. Int J Mol Sci 2019 Nov 15;20(22).
    doi: 10.3390/ijms20225745pubmed: 31731767google scholar: lookup
  15. Boere J, Malda J, van de Lest CHA, van Weeren PR, Wauben MHM. Extracellular Vesicles in Joint Disease and Therapy. Front Immunol 2018;9:2575.
    doi: 10.3389/fimmu.2018.02575pubmed: 30483255google scholar: lookup
  16. Duggan MJS, Kearney C, Baltrimaite M, Labberté MC, Gibney R, Brama PAJ. Refinement of the Lipopolysaccharide-Induced Synovitis Model in Equine Middle Carpal Joints. Animals (Basel) 2025 Aug 22;15(17).
    doi: 10.3390/ani15172474pubmed: 40941269google scholar: lookup
  17. Li H, Lyu Y, Wang R, Yu H, Lin M, Li Z, Zhong Y, Sheng P, Zhang K, Liao W, Bian L. Supramolecular drug-laden hydrogel based on structural tautomerization enhances drug delivery for rheumatoid arthritis treatment. Bioact Mater 2025 Nov;53:495-506.
    doi: 10.1016/j.bioactmat.2025.07.039pubmed: 40755847google scholar: lookup
  18. Scheike AS, Plomp S, Fugazzola MC, Meurot C, Berenbaum F, van Weeren PR, Tryfonidou MA, von Hegedus JH. The Anti-Inflammatory Effects of Liraglutide in Equine Inflammatory Joint Models. J Orthop Res 2025 May;43(5):893-903.
    doi: 10.1002/jor.26050pubmed: 39904754google scholar: lookup
  19. Varela L, van de Lest CHA, van Weeren PR, Wauben MHM. Synovial fluid extracellular vesicles as arthritis biomarkers: the added value of lipid-profiling and integrated omics. Extracell Vesicles Circ Nucl Acids 2024;5(2):276-296.
    doi: 10.20517/evcna.2024.14pubmed: 39698533google scholar: lookup
  20. Khandelia R, Hodgkinson T, Crean D, Brougham DF, Scholz D, Ibrahim H, Quinn SJ, Rodriguez BJ, Kennedy OD, O'Byrne JM, Brayden DJ. Reproducible Synthesis of Biocompatible Albumin Nanoparticles Designed for Intra-articular Administration of Celecoxib to Treat Osteoarthritis. ACS Appl Mater Interfaces 2024 Mar 27;16(12):14633-14644.
    doi: 10.1021/acsami.4c02243pubmed: 38483312google scholar: lookup
  21. Baig MMFA, Wong LK, Zia AW, Wu H. Development of biomedical hydrogels for rheumatoid arthritis treatment. Asian J Pharm Sci 2024 Feb;19(1):100887.
    doi: 10.1016/j.ajps.2024.100887pubmed: 38419762google scholar: lookup
  22. Kearney CM, Korthagen NM, Plomp SGM, Labberté MC, de Grauw JC, van Weeren PR, Brama PAJ. A Translational Model for Repeated Episodes of Joint Inflammation: Welfare, Clinical and Synovial Fluid Biomarker Assessment. Animals (Basel) 2023 Oct 12;13(20).
    doi: 10.3390/ani13203190pubmed: 37893914google scholar: lookup
Subscribe to our newsletter
Join 99,383 horse owners like you who receive our email updates on horse health and nutrition.